Registry Study for Patients with Ulcerative Colitis or Crohn’s Disease

Clinical Trial Title

Entyvio (vedolizumab) long-term safety study: An international observational prospective cohort study comparing vedolizumab to other biologic agents in patients with ulcerative colitis or Crohn's disease..

Clinical Trial Protocol Description:

This study is looking at patients who have been diagnosed with ulcerative colitis (UC) or Crohn’s disease (CD) and will be either starting vedolizumab (Entyvio®) or will be starting on another biologic medication for their disease. The purpose of this study is to obtain long-term safety information on the disease and medications that the patient received or are receiving for their inflammatory bowel disease. A description of this clinical trial will be available at, as required by U.S. law.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Have been diagnosed with ulcerative colitis or Crohn’s disease.
  • Are starting vedolizumab (Entyvio) or another biologic medication for their disease for the first time.
  • Are 18 years of age, or older.

This is a partial list of elgibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.

Study Details

Clinical Trial Investigator

Ece Mutlu, MD

Contact Information

GI Clinical Trials

(312) 942-3466